Loading...
Loading...
BCRX| Name | Value |
|---|---|
| Revenues | 92.8M |
| Cost of Revenue | 1.3M |
| Gross Profit | 91.5M |
| Operating Expense | 105.9M |
| Operating I/L | -14.4M |
| Other Income/Expense | -20.5M |
| Interest Income | 4.0M |
| Pretax | -35.0M |
| Income Tax Expense | 0.4M |
| Net Income/Loss | -35.4M |
BioCryst Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery of novel, oral, and small-molecule medicines. The company's revenue is generated through the marketing of peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza, and ORLADEYO, an oral serine protease inhibitor used to treat hereditary angioedema. Additionally, the company is developing BCX9930, an oral factor D inhibitor, and BCX9250, an oral activin receptor-like kinase-2 inhibitor, both in clinical trials for various diseases. BioCryst also has collaborations and in-license relationships with several pharmaceutical and research organizations.
